Biodesix price target lowered to $1.50 from $2.50 at Canaccord

Canaccord analyst Kyle Mikson lowered the firm’s price target on Biodesix (BDSX) to $1.50 from $2.50 and keeps a Buy rating on the shares. The firm said the target decrease is driven by lower near- and long-term revenue estimates after the company posted Q1 results that were below expectations.